Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

ICER Announces New $13.9M Grant from the Laura and John Arnold Foundation

By Institute for Clinical and Economic Review | November 1, 2017

The Institute for Clinical and Economic Review (ICER) today announced a three-year, $13.9 million grant from the Laura and John Arnold Foundation (LJAF). The funding will support ICER’s ongoing efforts to transform the way all new prescription drugs are evaluated and priced and will help advance the organization’s mission to ensure sustainable access to high-value care for all patients.

The new grant is LJAF’s latest investment in ICER, following a two-year, $5.2 million award made to the group in 2015 in support of its efforts to assess new drugs with the potential to significantly affect patient care and health system budgets. Since that time, ICER has produced reports evaluating drugs intended to treat high cholesterol, non-small cell lung cancer, multiple sclerosis, atopic dermatitis, and other conditions.

“Previous funding from LJAF has allowed ICER to lead a national discussion about prescription drug pricing, and pharmaceutical companies are now beginning to reference ICER’s value-based benchmarks when launching new treatments in the U.S.,” noted Steven D. Pearson, MD MSc, President of ICER. “However, prices for the majority of medicines still do not reflect the clinical benefit they deliver. By expanding the frequency, scope and reach of our value-based assessments, we will continue to move the country toward a more transparent healthcare system that rewards medical innovation while allowing patients to access the treatments they need.”

With the new funding, ICER will:

  • Introduce a new annual report on drug price increases to help identify unjustified price increases;
  • Perform more frequent evidence updates to existing reviews;
  • Collaborate with employers and payers on innovative benefit design and reimbursement programs;
  • Launch a fourth public deliberation council;
  • Begin a visiting fellowship program; and
  • Further develop its methods around stakeholder engagement.

“We have seen ICER fill a critical gap in our health care system by providing the information needed to start transparent conversations about the pricing of prescription drugs,” explained LJAF President and Chief Executive Officer Kelli Rhee. “Through the continuation and expansion of its work, ICER can help stakeholders build a system in which payers, policymakers, drug manufacturers, and others collaborate to bring new drugs to market in a way that allows for optimal patient access, without creating unsustainable strains on health care budgets.”


Filed Under: Drug Discovery

 

Related Articles Read More >

Lokavant’s Spectrum v15 uses AI to cut trial-feasibility modeling from weeks to minutes
Prime time for peptide-based drug discovery 
Why smaller, simpler molecular glues are gaining attention in drug discovery
Glass vial, pipette and woman scientist in laboratory for medical study, research or experiment. Test tube, dropper and professional female person with chemical liquid for pharmaceutical innovation
Unlocking ‘bench-to-bedside’ discoveries requires better data sharing and collaboration
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE